MGC018 + MGD019 for Solid Tumors

Recruiting in Palo Alto (17 mi)

+10 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: MacroGenics

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests two experimental drugs on patients with advanced cancers that haven't responded to other treatments. One drug aims to kill cancer cells directly, while the other boosts the immune system to fight the cancer.

Eligibility Criteria

This trial is for adults with advanced solid tumors, including specific cancers like prostate, melanoma, pancreatic, liver, ovarian, and kidney cancer. Participants must have a life expectancy of at least 12 weeks and should have tried approved treatments already. They need to be able to consent to the study's procedures and agree to use effective contraception. People with certain medical conditions or those who've had other recent malignancies are not eligible.

Inclusion Criteria

I have an advanced solid tumor, such as prostate, melanoma, pancreatic, liver, ovarian, or kidney cancer.

Your organs are working well, as shown in your lab test results.

I have an advanced solid tumor such as prostate, melanoma, pancreatic, liver, ovarian, or kidney cancer.

Exclusion Criteria

I have a history of Guillain-Barre syndrome, myasthenia gravis, or similar conditions.

I have had a stem cell or organ transplant before.

I haven't had treatment for another cancer, except for certain skin, prostate cancers, or early-stage cancers, in the last 2 years.

Participant Groups

The trial tests vobramitamab duocarmazine (MGC018) in combination with lorigerlimab on patients with various advanced solid tumors. It aims to evaluate safety, tolerability and initial effectiveness of these drugs given every four weeks up to two years unless there's disease progression or unacceptable side effects.

Group I: Cohort Expansion Experimental Treatment 2 Interventions

maximum tolerated dose of vobramitamab duocarmazine and lorigerlimab IV every 4 weeks

Group II: Cohort 5 Experimental Treatment 2 Interventions

vobramitamab duocarmazine at dose level 4 and lorigerlimab IV every 4 weeks

Group III: Cohort 4 Experimental Treatment 2 Interventions

vobramitamab duocarmazine at dose level 3 and lorigerlimab IV every 4 weeks

Group IV: Cohort 3 Experimental Treatment 2 Interventions

vobramitamab duocarmazine at dose level 2 and lorigerlimab IV every 4 weeks

Group V: Cohort 2 Experimental Treatment 2 Interventions

vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks

Group VI: Cohort 1 Experimental Treatment 2 Interventions

vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks

Group VII: Cohort -1 Experimental Treatment 2 Interventions

vobramitamab duocarmazine at dose level -1 and lorigerlimab intravenously (IV) every 4 weeks

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Stephenson Cancer Center, The University of Oklahoma Oklahoma City, OK

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, MD

University of California, Los Angeles Los Angeles, CA

University of California, San Francisco San Francisco, CA

More Trial Locations

Who Is Running the Clinical Trial?

MacroGenics Lead Sponsor

References